Literature DB >> 12695996

Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease.

Miikka Peltomaa1, Gail McHugh, Allen C Steere.   

Abstract

It has been suggested that a <4-fold decline in the immunoglobulin G (IgG) antibody response to the VlsE sixth invariant region peptide of Borrelia burgdorferi within 6 months after antibiotic treatment may indicate spirochetal persistence in Lyme disease. We studied the response to this peptide in 77 patients with early or late disease, for whom archival samples were available at the time of antibiotic treatment and approximately 6 months or years later. Eight (33%) of the 24 patients with early manifestations and 18 (86%) of the 21 patients with late manifestations had a <4-fold decline in IgG anti-VlsE titers approximately 6 months after successful antibiotic treatment. Of 32 additional patients, 13 (50%) with early manifestations and 5 (83%) with late manifestations still had positive anti-VlsE titers 8-15 years after successful antibiotic treatment. We conclude that persistence of the anti-VlsE antibody response for months or years after antibiotic treatment cannot be equated with spirochetal persistence in Lyme disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695996     DOI: 10.1086/374376

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  The emergence of Lyme disease.

Authors:  Allen C Steere; Jenifer Coburn; Lisa Glickstein
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis.

Authors:  Mario T Philipp; Gary P Wormser; Adriana R Marques; Susan Bittker; Dale S Martin; John Nowakowski; Leonard G Dally
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

3.  Use of Peptide library screening to detect a previously unknown linear diagnostic epitope: proof of principle by use of lyme disease sera.

Authors:  Carl V Hamby; Marta Llibre; Sandeepa Utpat; Gary P Wormser
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

4.  Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.

Authors:  Thomas B Ledue; Marilyn F Collins; John Young; Martin E Schriefer
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

Review 5.  Laboratory diagnosis of Lyme disease: advances and challenges.

Authors:  Adriana R Marques
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

6.  Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis.

Authors:  R V Fleming; A R Marques; M S Klempner; C H Schmid; L G Dally; D S Martin; M T Philipp
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-08       Impact factor: 3.267

7.  Prospective study of serologic tests for lyme disease.

Authors:  Allen C Steere; Gail McHugh; Nitin Damle; Vijay K Sikand
Journal:  Clin Infect Dis       Date:  2008-07-15       Impact factor: 9.079

8.  Detection of antibodies to decorin-binding protein A (DbpA) and DbpB after infection of dogs with Borrelia burgdorferi by tick challenge.

Authors:  Darby G Oldenburg; Dean A Jobe; Steven D Lovrich; Rhonda L LaFleur; Douglas W White; Jennifer C Dant; Steven M Callister
Journal:  J Vet Diagn Invest       Date:  2020-03-20       Impact factor: 1.279

9.  Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late manifestation of the infection.

Authors:  Kathryn L Jones; Robert J Seward; Gil Ben-Menachem; Lisa J Glickstein; Catherine E Costello; Allen C Steere
Journal:  Clin Immunol       Date:  2009-04-02       Impact factor: 3.969

10.  Detection of IFN-γ Secretion by T Cells Collected Before and After Successful Treatment of Early Lyme Disease.

Authors:  Steven M Callister; Dean A Jobe; Aleksandra Stuparic-Stancic; Misato Miyamasu; Jeff Boyle; Raymond J Dattwyler; Paul M Arnaboldi
Journal:  Clin Infect Dis       Date:  2016-03-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.